Last reviewed · How we verify
Combination DSCG and Reproterol
DSCG inhibits mast cell degranulation and reduces inflammation, while Reproterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle.
DSCG inhibits mast cell degranulation and reduces inflammation, while Reproterol is a beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle. Used for Asthma, Chronic obstructive pulmonary disease (COPD).
At a glance
| Generic name | Combination DSCG and Reproterol |
|---|---|
| Sponsor | MEDA Pharma GmbH & Co. KG |
| Drug class | mast cell stabilizer and beta-2 adrenergic receptor agonist |
| Target | beta-2 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Respiratory |
| Phase | Phase 2 |
Mechanism of action
DSCG (disodium cromoglycate) is a mast cell stabilizer that prevents the release of histamine and other mediators from mast cells, thereby reducing inflammation. Reproterol, on the other hand, is a beta-2 adrenergic receptor agonist that stimulates the relaxation of bronchial smooth muscle, leading to bronchodilation.
Approved indications
- Asthma
- Chronic obstructive pulmonary disease (COPD)
Common side effects
- Headache
- Nausea
- Tachycardia
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combination DSCG and Reproterol CI brief — competitive landscape report
- Combination DSCG and Reproterol updates RSS · CI watch RSS
- MEDA Pharma GmbH & Co. KG portfolio CI